These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22275397)

  • 1. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.
    Haas SK; Freund M; Heigener D; Heilmann L; Kemkes-Matthes B; von Tempelhoff GF; Melzer N; Kakkar AK;
    Clin Appl Thromb Hemost; 2012; 18(2):159-65. PubMed ID: 22275397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    Agnelli G; George DJ; Kakkar AK; Fisher W; Lassen MR; Mismetti P; Mouret P; Chaudhari U; Lawson F; Turpie AG;
    N Engl J Med; 2012 Feb; 366(7):601-9. PubMed ID: 22335737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials.
    Hicks LK; Cheung MC; Ding K; Hasan B; Seymour L; Le Maître A; Leighl NB; Shepherd FA
    Cancer; 2009 Dec; 115(23):5516-25. PubMed ID: 19711465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin.
    Saccullo G; Malato A; Raso S; Santoro M; Zammit V; Casuccio A; Siragusa S
    Am J Hematol; 2012 Apr; 87(4):388-91. PubMed ID: 22374861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
    Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism.
    Marchena PJ; Nieto JA; Guil M; García-Bragado F; Rabuñal R; Boccalon H; Trujillo-Santos J; Monreal M;
    Thromb Haemost; 2012 Jan; 107(1):37-43. PubMed ID: 22116496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.
    Schellong SM; Haas S; Greinacher A; Schwanebeck U; Sieder C; Abletshauser C; Bramlage P; Riess H
    Expert Opin Pharmacother; 2010 Dec; 11(18):2953-61. PubMed ID: 20950224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.
    Fuentes HE; Oramas DM; Paz LH; Casanegra AI; Mansfield AS; Tafur AJ
    Thromb Res; 2017 Jun; 154():28-34. PubMed ID: 28402864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin.
    Haas S; Wolf H; Kakkar AK; Fareed J; Encke A
    Thromb Haemost; 2005 Oct; 94(4):814-9. PubMed ID: 16270636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and usefulness of low molecular weight heparins and unfractionated heparins in patients with acute stroke.
    Kiphuth IC; Köhrmann M; Huttner HB; Schellinger PD
    Expert Opin Drug Saf; 2009 Sep; 8(5):585-97. PubMed ID: 19614560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism.
    Hirsh J; Siragusa S; Cosmi B; Ginsberg JS
    Thromb Haemost; 1995 Jul; 74(1):360-3. PubMed ID: 8578485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboprophylaxis during chemotherapy in patients with advanced cancer.
    Agnelli G; Verso M
    Thromb Res; 2010 Apr; 125 Suppl 2():S17-20. PubMed ID: 20433999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
    Couturaud F; Julian JA; Kearon C
    Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.